Standard BioTools Expects Q4 2025 Revenue of Approximately $56M

Standard BioTools announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56M and revenue from continuing operations of approximately $24M. For the full year 2025, the Company expects combined company revenue of approximately $185M and revenue from continued operations of approximately $85M. Our 2025 performance reflected steady execution, ending the year above our guidance range and exceeding expectations for both combined and continuing operations," said Michael Egholm, CEO. "Amid a shifting macro backdrop, the team remained focused - managing what we could control to drive the business forward. We continued our path toward profitability, taking targeted actions to streamline the organization and sharpen our operating model. Grounded in continuous improvement, we optimized workflows, improved our cost structure and drove rigor across the Company. These efforts strengthened our foundation and leave us exiting the year a leaner organization and a more resilient business. As we look to 2026, the sale of SomaLogic to Illumina remains on track to close in the first half of the year. At close, we expect to have approximately $550M in cash and a base business on its way to positive adjusted EBITDA - a combination that creates real strategic flexibility. With an experienced team, a simplified footprint and substantial cash, we are well positioned to pursue disciplined M&A as we work to build a diversified leader in life sciences."